Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 7Mastocytosis, Systemic 5Recurrence 3Leukemia, Mast-Cell 2Glioma 2Sarcoma 1Neoplasms 1Mastocytosis 1Glioblastoma 1GIST 1Central Nervous System Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × avapritinib × Clear all
NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Blueprint Medicines Corporation

Phase 1/2 Completed
29 enrolled
CNS

Glioma, Recurrence, Central Nervous System Neoplasms

NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Blueprint Medicines Corporation

Phase 1 Completed
86 enrolled 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡